We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2367:HKEXGiant Biogene Holding Co., Ltd. Analysis

Data as of 2026-09-05 - not real-time

HK$26.62

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

At HKD 26.62, Giant Biogene Holding Co., Ltd. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Over a rolling month the price has lost 7.9%. Momentum indicators put RSI at 43.3 (neutral) with MACD reading bearish. Watch HKD 25.58 as support and HKD 30.48 as the nearer resistance level.
The shares look undervalued at 14.5 times earnings, though no sector average was available for comparison. Analyst price targets sit 49.8% above the current price. Revenue is contracting at 6.3% on a 31.4% profit margin. The 2.41% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 44.0%, a beta of 0.24 and a maximum drawdown of 61.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.

Top Market Events

Detailed price information for North State Telecommunications C NORSB from The Globe and Mail including charting and...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 30.96
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 30.96
  • Analyst targets imply +49.8% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Analyst targets imply +49.8% versus the current price
  • Profit margin of 31.4% is healthy
  • Revenue contracting at -6.3%

Key Metrics & Analysis

Financial Health

Revenue Growth-6.30%
Profit Margin31.42%
P/E Ratio14.5
ROE18.01%
ROA9.80%
Debt/Equity0.13
P/B Ratio2.6

Technical Analysis

TrendBearish
RSI43.3
SupportHK$25.58
ResistanceHK$30.48
MA 20HK$27.80
MA 50HK$28.01
MA 200HK$30.96
MACDBearish
VolumeDecreasing
Fear & Greed Index95.48

Valuation

Target PriceHK$39.88
Upside/Downside49.81%
GradeUndervalued
TypeValue
Dividend Yield2.41%

Risk Assessment

Beta0.24
Volatility44.01%
Sector RiskLow
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.